OpGen (NASDAQ:OPGN) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a report released on Tuesday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Stock Performance

Shares of NASDAQ:OPGN opened at $3.22 on Tuesday. The business has a fifty day moving average price of $1.37 and a 200-day moving average price of $1.46. OpGen has a 1-year low of $0.53 and a 1-year high of $8.40.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.